Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,167,715.00 in Stock

Posted by Stanley Muller on Jul 2nd, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $543.97, for a total value of $5,167,715.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,037,856.61. This trade represents a 19.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Trading Up 1.0%

UTHR opened at $547.15 on Thursday. The stock has a market capitalization of $23.22 billion, a P/E ratio of 20.20, a PEG ratio of 1.78 and a beta of 0.57. The stock has a 50-day moving average price of $559.06 and a 200-day moving average price of $527.20. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue was down 1.6% compared to the same quarter last year. During the same period last year, the business posted $6.63 earnings per share. On average, equities research analysts predict that United Therapeutics Corporation will post 26.63 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in UTHR. Leuthold Group LLC boosted its stake in shares of United Therapeutics by 41.4% during the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after purchasing an additional 3,126 shares in the last quarter. UBS Group AG grew its holdings in shares of United Therapeutics by 45.3% during the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after acquiring an additional 70,445 shares during the period. Perpetual Ltd bought a new position in shares of United Therapeutics in the 4th quarter worth approximately $1,059,000. Brookstone Capital Management raised its position in shares of United Therapeutics by 25.4% in the 4th quarter. Brookstone Capital Management now owns 6,622 shares of the biotechnology company’s stock worth $3,227,000 after acquiring an additional 1,342 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of United Therapeutics by 88.6% during the fourth quarter. SG Americas Securities LLC now owns 26,960 shares of the biotechnology company’s stock valued at $13,136,000 after purchasing an additional 12,663 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of several analyst reports. Cantor Fitzgerald upped their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Bank of America boosted their target price on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. HC Wainwright increased their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Finally, TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

Check Out Our Latest Stock Analysis on UTHR

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.